Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 New SLE Classification Criteria Perform Well in Early Disease and Across Sexes, Ethnicities
2 In Case You Missed EULAR 2020 E-CONGRESS: Advances in the Management of Refractory Gout
3 EULAR 2020: What to Expect
4 ICD 10 Algorithm Accurately Identifies Rheumatoid Arthritis Patients
5 Aspirin May Be Considered for Primary Prevention of Cardiovascular Disease in Rheumatic Diseases
6 Eular 2020 | BMJ
7 EULAR COVID-19 Recommendations Say Continue Medications, but Vaccinate
8 Adalimumab Serum Levels Not Predictive of Response to Next Anti-Rheumatic Drug
9 EULAR Recommendations for Rheumatic Disease Management During the COVID-19 Pandemic
10 EULAR Provides COVID-19 Recommendations
11 EULAR president touts 'success stories' en route to 2023 goals
12 Revised EULAR guidelines for DMARDs embrace 'multiple drugs with differing modes of action'
13 EULAR COVID-19 registry yields first study of therapy impact on hospitalization
14 Differentiating oligoarthritis, polyarthritis marks 'big change' in EULAR guidelines for PsA
15 EULAR Issues Recommendations on COVID-19 And Rheumatic, Musculoskeletal Conditions
16 EULAR: Nonphysician health providers should be part of fragility fracture management
17 Literature Review of 2019 EULAR Recommendations for PsA Management Indicates Efficacy, Safety of Pharmacologic Treatment
18 EULAR advises 'cautious tapering' of DMARDs for patients with sustained PsA remission
19 EULAR 2020: Thrombosis risk particularly high for people suffering
20 EULAR launches COVID-19 rheumatic disease reporting database
21 DMARDs for Patients With Rheumatoid Arthritis-Associated ILD
22 EULAR releases first guidance for intra-articular injections in arthropathies
23 Updated EULAR recommendations revamp treatment targets for lupus nephritis
24 EULAR: Rheumatologist, oncologist collaboration 'pivotal' to enhance checkpoint inhibitor management
25 Updated EULAR recommendations for RA allow larger role for JAK inhibitors
26 EULAR 2020: highlights from the European e-Congress of Rheumatology
27 EULAR: Early and intensive treatment of rheumatoid arthritis reduces fatigue
28 Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study
29 EULAR Studies Explore Value of Biosimilar Switching
30 EULAR Report: Physicians Increasingly Pass on Biosimilars
31 COVID-19 and Rheumatic Disease Findings Reported at EULAR
32 EULAR Criteria Predicts Progression to Rheumatoid Arthritis in Patients With Hand Arthralgias
33 EULAR/ACR 2019 SLE criteria fail to outperform ACR 1997, SLICC 2012
34 EULAR 2020: Taltz continues to show consistent efficacy in PsA
35 AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
36 European Commission Grants Marketing Authorization for Jyseleca (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis | Small Molecules | News Channels
37 EULAR 2020 Roundup: Men Get Sjogren's Too
38 Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress
39 EULAR 2020: Novartis underscores importance of Cosentyx
40 EULAR advocates deployment of health care professionals -- study confirms effectiveness
41 EULAR Report: High Disease Activity in RA Linked to Venous Thromboembolism
42 EULAR Report: Dual Cause of Increased CV Risk in Ankylosing Spondylitis Needs Attention
43 EULAR: New data reinforce benefits of Orencia for early RA patients
44 Updated EULAR Recommendations for Rheumatoid Arthritis Management With DMARDs
45 Updated ACR/EULAR Criteria May Classify SLE Earlier
46 EULAR 2020 | Guselkumab benefits maintained over 1 year in psoriatic arthritis
47 Lesser Damage Accrual Among Patients Not Fulfilling the 2019 EULAR/ACR Criteria for SLE
48 EULAR Report: Nurse-Led Care May Improve RA Patient-Reported Outcomes
49 EULAR publishes updated recommendations for treating people with psoriatic arthritis
50 EULAR publishes recommendations for management of rheumatic immune-related adverse events
51 The European League Against Rheumatism, EULAR, launches Virtual Research Centre
52 EULAR launches COVID-19 RMD reporting database as part of Global Rheumatology Alliance
53 Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
54 Patients who fail to meet 2019 EULAR/ACR lupus criteria amass less damage
55 ACR and EULAR release new classification criteria for IgG4-related disease
56 EULAR 2020: Lilly Shares New Data for OLUMIANT® in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)
57 ACR, EULAR release first classification criteria for IgG4
58 EULAR: Amputations of body parts: The combination of diabetes and gout significantly increases
59 Lack of EULAR/ERA-EDTA Response Predicts Chronic Kidney Disease in Patients With Lupus Nephritis
60 Active Conventional Therapy Linked to High, Early Remission Rates in Rheumatoid Arthritis
61 EULAR Report: Cesarean Deliveries Higher in Spondyloarthritis
62 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease
63 EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus
64 BIOCAD presents results of clinical trial proving efficacy of netakimab at EULAR 2020
65 UCB Shares Breadth of Innovative New Data from Rheumatology Portfolio for EULAR 2020 E-Congress
66 EULAR 2020: Lilly's TALTZ® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
67 EULAR: All rheumatology providers should be familiar with disease features, routine therapies
68 EULAR Report: Ixekizumab Approved for Axial Spondyloarthritis
69 BRIEF-Biogen Presents Positive Cutaneous Lupus Erythematosus Data At Eular
70 Comparing the Latest Psoriatric Arthritis Guidelines
71 EULAR: Timely detection of axial spondyloarthritis
72 EULAR: Hydroxychloroquine use in lupus patients 'does not seem to prevent COVID-19'
73 Lack of EULAR/ERA-EDTA lupus response at 1 year predicts chronic kidney disease
74 Evaluating the Presence and Impact of Comorbidities in Rheumatoid Arthritis
75 Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
76 Rigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress
77 Etanercept linked to elevated risk for anterior uveitis in patients with SpA
78 Avacopan May Be Safe, Efficacious, and Superior to Other Treatments in ANCA-Associated Vasculitis
79 Do TNFis Reduce the Risk for Progression to PsA in Patients With Psoriasis?
80 Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020) | Proteins and Peptides | News Channels
81 Rheumatology Drugs Explored for COVID-19 in the Spotlight
82 Updated 2019 EULAR Recommendations for Vaccination in Adults With Autoimmune Inflammatory Rheumatic Diseases
83 AbbVie at EULAR
84 Opioid Use Up After TNF Inhibitor for Inflammatory Arthritis
85 EULAR Develops Points to Consider for Big Data Analysis and Use in Rheumatic and Musculoskeletal Diseases
86 Real-World Results and Long-Term Safety Data for Secukinumab
87 Expert view: 2019 update of EULAR recommendations for the management of SLE
88 Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism (EULAR) E-Congress 2020
89 TNF Inhibitors Cut Odds of VTE in RA Patients
90 Opioid Use on the Rise in Europe
91 Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
92 EULAR Recommendations for Managing Antiphospholipid Syndrome in Adults
93 BRIEF-Aurinia Presents Aurora Pivotal Trial Subgroup Analysis At Eular
94 ARCTIC REWIND supports TNF inhibitor continuation in sustained RA remission
95 Interferon Inhibition With Anifrolumab Reduces Disease Activity in Systemic Lupus Erythematosus
96 2019 EULAR/ACR Recommendations for SLE Classification Criteria
97 Belimumab plus standard therapy 'significantly improves' lupus nephritis renal response
98 EULAR: Nurses should be part of rheumatology disease control
99 Biologic, targeted synthetic DMARDs linked to increased herpes zoster risk
100 Voclosporin Beats Standard of Care in Lupus Nephritis